NanoVibronix, Inc. (NAOV)

0.6900 -0.0525 (-7.07%) At close: 04:00PM EDT

NanoVibronix, Inc.

525 Executive Boulevard
Elmsford, NY 10523
United States
914 233 3004
https://www.nanovibronix.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brian M. Murphy	CEO & Director	342.5k	N/A	1957
Mr. Stephen R. Brown CPA	Chief Financial Officer	276.5k	N/A	1956
Dr. Harold Jacob M.D.	Chief Medical Officer & Director	N/A	N/A	1954
Mr. Amir Rippel	Vice President of Marketing	N/A	N/A	N/A
Ms. Lindsey Harrison	Vice President of Sales	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

Corporate governance

NanoVibronix, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.